Related Experiment Videos
[Use of carvedilol in daily practice]
A Cohen-Solal1, D Logeart, C Guiti
1Service de Cardiologie, Hôpital Beaujon, 100, boulevard du Général Leclerc, 92110 Clichy, France.
Insights
Beta-blockers are a key heart failure treatment, but challenging to administer. This review focuses on carvedilol, the only approved beta-blocker for heart failure, examining its practical use in patients.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Beta-blockers are established as a primary therapy for heart failure.
- Clinical application of beta-blockers in heart failure presents significant challenges.
Purpose of the Study:
- To review the practical aspects of using carvedilol in heart failure patients.
- To address the challenges associated with beta-blocker therapy in heart failure.
Main Methods:
- Literature review of studies on beta-blocker use in heart failure.
- Analysis of clinical data pertaining to carvedilol administration.
- Examination of practical treatment considerations for carvedilol.
Main Results:
- Carvedilol is the sole beta-blocker with marketing authorization for heart failure.
- The review synthesizes practical information for carvedilol treatment.
- Challenges in beta-blocker therapy are highlighted.
Conclusions:
- Carvedilol offers a viable option for heart failure management despite general challenges with beta-blockers.
- Practical guidance on carvedilol use is essential for effective heart failure treatment.
Abstract:
Studies conducted over recent years have definitively confirmed beta-blockers as the major treatment for heart failure. However, they are difficult to use and, to date, only carvedilol has been granted a Marketing Authorisation for this indication. The practical aspects of treatment with carvedilol in these patients are reviewed.